NEJM· Ahmad Masri Martin S. Maron Ankit Bhatia Maria Luisa Peña-Peña Mark V. Sherrid Estevao Lanna Figueiredo Michael Arad Roberto Barriales-Villa Lubna Choudhury Brian L. Claggett Caroline J. Coats Edileide de Barros Correia Juan Pablo Costabel Perry M. Elliott Jorge E. Silva Enciso Pablo Garcia-Pavia Junbo Ge Sheila M. Hegde Gregory D. Lewis Renato D. Lopes Matthew W. Martinez Mathew S. Maurer Zi Michael Miao Michelle Michels Sumeet S. Mitter Jesus E. Pino Moreno Iacopo Olivotto Anjali T. Owens Steen H. Poulsen Florian Rader Ethan J. Rowin P. Christian Schulze Robert Sepp Nikhil Sikand Scott D. Solomon John A. Spertus Charles Teale Xiaoyan Zhao Punag H. Divanji Stephen B. Heitner Daniel L. Jacoby Stuart Kupfer Fady I. Malik Joel Salazar-Mendiguchía Amy Wohltman Shu Zhuo and Carolyn Y. Hothe ACACIA-HCM Investigators*·· 2026-08-28AI 评分33
Aficamten 治疗症状性非梗阻性肥厚型心肌病
Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
AI 导读
Aficamten 在症状性非梗阻性肥厚型心肌病（nHCM）患者中显著改善运动能力与症状。该随机对照试验显示，治疗组主要终点（运动时峰值耗氧量变化）较安慰剂组显著改善，且纽约心脏协会（NYHA）心功能分级和肥厚型心肌病症状评分均获改善。安全性方面，治疗组射血分数下降事件更常见，但多数为可逆性。
来源：NEJM · nejm.org